Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges
The molecular chaperone Hsp90 holds great promise as a cancer drug target, despite some of the initial clinical trials of Hsp90 inhibitor drugs having not lived up to expectation. Effective use of these drugs will benefit greatly from a much more detailed understanding of the factors that contribute...
| Prif Awduron: | , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
MDPI AG
2011-10-01
|
| Cyfres: | Pharmaceuticals |
| Pynciau: | |
| Mynediad Ar-lein: | http://www.mdpi.com/1424-8247/4/11/1400/ |